

AGENDA AUDIT COMMITTEE MEETING September 16, 2019 11:00am-12:30pm NH Insurance Department Walker Building, Room 274 Call In #: 646 558 8656 Meeting ID: 765 111 990

Committee Members: David Sky, Chair; Susan Tenney, Vice Chair; Elizabeth Daly; Jason Margus

Administrator Staff: Patrick Miller, Keith Nix, Erin Meagher

Invited Guests: Dona Murray and Arlene Folsom, Bank of New Hampshire, Wendy Parker, NHVA Board Member

11:00am	1. Call to Order
11:00-11:10am	2. Review and Accept August 6, 2019 Audit Committee Meeting Minutes
	– Vote
11:10-11:30am	3. Investment Policy Recommendations, Dona Murray and Arlene
	Folsom, Bank of New Hampshire
11:30-12:20pm	4. Administrator Updates
	a. CY2020 Assessment Review and Discussion – Vote
12:20-12:30pm	5. New Business
12:30pm	6. Call to Adjourn

Upcoming NHVA Meetings:

- September 25, 2019, 8:30-10:30am
- November 15, 2019, 9-11:30am



1		
2	M	INUTES
3	Audit Com	mittee Meeting
4		st 6, 2019
5	-	n to 10:30am
6		Sky, Chair, Audit Committee
7		
8		
9	A meeting of the Audit Committee of the Board of Dire	ctors of the New Hampshire Vaccine Association (NHVA) was
10	held in person at the offices of the NH Department of I	nsurance in Concord, NH with a quorum present.
11		
12	The meeting was called to order by Mr. Sky at 8:59am.	
13 14	1 Malasura and Interductions	
14 15	I. Welcome and Introductions	
16	Attendance – The following individuals attended the m	peeting, including by phone (P) as indicated:
17		
	Committee Members:	Other Attendees:
	David Sky, NHID, Chair	Patrick Miller, Helms & Company
	Susan Tenney, HPHC, Vice Chair	Erin Meagher, Helms & Company
	Elizabeth Daly, NH DHHS	Keith Nix, Helms & Company
	Jason Margus, Anthem (P)	John Hastings, Helms & Company
		Karen Carew, Carew & Wells
18	Mr. Miller announced he was recording the meeting.	
19		
20	II. Review and Accept April 11, 2019 Audit Com	nittee Minutes
21	NOTE DECODDED. On another to Ma Tanana da	dha Ma Daha itaana waxaina aada
22 23	VOTE RECORDED: On a motion by Ms. Tenney, seconde	
25 24	VOTED: To accept the April	11, 2019 Audit Committee minutes as presented.
25	III. Review of FY2019 Draft Audit Report, Karen (Carew Carew & Wells PLLC
26		
27	Ms. Carew reviewed several documents provided to th	e Committee including the Governance Letter, Management
28		explained there was one change last year in the Basis of
29		sets <i>Without</i> Donor Restrictions, those currently available at
30		- currently \$250,000 designated and Net Assets With Done
31		e and simply rewording from Unrestricted Net Assets and
32	Temporarily Restricted Net Assets.	
33		
34	Ms. Carew asked the group to turn to the Draft Financ	ial Statements to the Independent Auditors' Report on page
35		ments are fairly presented and reliable, and the organization
36		GAAP, and a clean opinion letter has been issued. Ms. Carew
37		Sheet and pointed out Net Assets at the bottom of the page.
38	-	ed by the RSA as working capital for the administration of the
39		nor Restrictions. All other funds are listed under Net Assets
40	With Donor Restrictions.	
41		



42 As the Board continues their discussion in September regarding the development of a \$5M reserve fund, once 43 designated, the Net Assets Without Donor Retractions would increase. The Board could designate whatever dollar 44 amount they choose and designate it for any purpose they choose. General discussion ensued and a few clarifying 45 questions were answered.

46

47 Ms. Carew continued to the Statement of Cash Flow highlighting the largest change noted in the Draft Financial 48 Statements during the past year was the increase in cash. This was a result primarily of the TRICARE settlement, the 49 Tufts recoupment, and the reduction of the remittance amount to the State of New Hampshire. Moving to the 50 Statement of Activities and Changes in Net Assets, Ms. Carew stated there was a large increase in Operating Expenses 51 over the past year, specifically attributed to the remittance to Washington Vaccine Association for the TRICARE work 52 and transitional costs while changing Administrators.

52 53

57

59

60

61

62

63

54 Moving to the Notes to Financial Statements Ms. Carew highlighted a change in the basis of presentation on page 55 16 which describes a new requirement for all Program Expenses, Management and General Expenses and Total 56 Expenses to be listed together in one place.

- 58 During Ms. Carew's presentation, the following questions and changes were outlined by the group:
 - Ms. Daly asked that wherever "Remittance to TRICARE Washington" is listed in the report, that it be changed to "Remittance to Washington Vaccine Association" to clarify the payments that were made to WVA for the TRICARE project.
 - Mr. Miller mentioned a spelling error on page 12 of the packet whereby "Restrictions" needs correction under "Net Assets Without Donor Restrictions".
- Ms. Carew referred to a new disclosure on page 18 of the packet Section C Current Resources as it relates to the
 Board's ongoing discussion of reserving \$5M in the future. This section of the audit report will specify the reserve
 in the future. General discussion ensued regarding the need to provide stable assessment rates in the future. Mr.
- 68 Miller reminded the group that the discussions to reserve \$5M began at last Septembers Board meeting. It is 69 anticipated this will be included as a formal discussion and vote at the September 25, 2019 Board meeting.
- 70

Ms. Carew completed the review of the Notes to Financial Statements including brief comments on the TRICARE
 Assessment and Minuteman Health, Inc.'s liquidation.

73

The Board of Director's letter (page 6 of the packet) was reviewed. Ms. Carew stated there were absolutely no problems conducting the audit. Her team found Helms & Company enjoyable and very easy to work with. Carew & Wells brought an onsite staff of three for the audit and due to Helms cooperation and the provision of written controls prior to the audit they were able to complete testing and had very clean audit quickly. Ms. Carew stated that for a first transition year as the new Administrator, Helms did a great job. Mr. Miller shared with the group what a pleasure it was to work with Ms. Carew and her team through the audit process.

80

81 Ms. Carew reported there were no uncorrected or material misstatements. A few suggestions were made in the 82 Management Letter (page 21 of the packet) to the Administrator regarding: a review/revision of the late payment 83 interest policy for Board consideration, implementing trial balance account numbers, reviewing with the Board the 84 possible need for general liability insurance, and reviewing with the Board the possibility of granting check signing 85 authority up to a certain limit to management. General discussion ensued and Ms. Carew indicated Helms had 86 already reviewed and responded to all the recommendations less the check signing authority.

- 87
- 88 Mr. Miller stated a new Interest Policy will be proposed later in the meeting and that Helms has reached out to the
- insurance Broker for review of the need for general liability insurance. The Committee discussed the check signing
 authority recommendation made by Ms. Carew. It is a cumbersome process, but Mr. Miller shared that at this point
 - 3



91	the controls are in place and he is comfortable with the current arrangement of Board members having signing
92	authority. Ms. Tenney agreed.
93	
94	Mr. Sky proposed moving into Executive Session so the Audit Committee could have a brief discussion with Ms.
94 95	
96	Carew.
90 97	VOTE RECORDED: On a motion by Mr. Sky, seconded by Ms. Daly, by roll call it was
98	VOTE RECORDED. On a motion by Win. Sky, seconded by Wis. Daily, by for can it was VOTED: To move into Executive Session at 9:23 am.
98 99	
	<u>Yes</u> <u>No</u>
100	Beth Daly X
101	Jason Margus X
102	David Sky X
103	Susan Tenney X
104	
105	The Helms Team and invited guests from Bank of New Hampshire then left the meeting and were invited back into
106	the room at 9:25 am.
107	
108	VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously
109	VOTED: To recommend to the Board of Directors at the next Board meeting scheduled for
110	September 25, 2019 to accept the FY2019 draft Audit Report by Carew & Wells
111	as amended above.
112	
113	Ms. Carew agreed to make the changes outlined above and return a draft copy to Mr. Miller for distribution to the
114	group (revised version is included in these minutes).
115	
116	IV. Investments Review, Dona Murray and Arlene Folsom, Bank of New Hampshire
117	
118	Mr. Miller provided a brief overview of the meetings he has had with the Bank of New Hampshire (BONH) to
119	understand how we can work to increase high rates of return on investment income as well as future investment
120	strategies for the anticipated creation of the \$5M reserve fund.
121	
122	Ms. Folsom thanked the group for their time today. She acknowledged the long relationship the BONH has had with
123	the NH Vaccine Association. Given Ms. Folsom's relative newness to the relationship, she turned the presentation
124	over to Ms. Murray.
125	
126	Ms. Murray provided a brief history outlining NHVA's investment relationship with BONH since 2005. The initial
127	investment strategy consisted of CDs and the eventual investment of \sim \$15M in assets in over 120 laddered
128	securities.
129	
130	In the spring of 2016, the former Administrator began depositing all cash in the lower-yielding Insured Cash Sweep
131	(ICS) account. Wealth Management representatives attempted to discuss better investment alternatives, but there
132	was no Administrator response, and most of the cash remained deposited in ICS.
133	
134	Ms. Murray explained the ICS account is a courtesy account the BONH provides to their clients that require FDIC
135	insurance but have balances above the \$250,000 threshold. When Helms took over the Administration of NHVA the
136	rate was 0.01%. At the request of Helms, two rate increases were provided – in August 2018 the rate was increased
137	to 1.25% and then in November 2018 up to 2.00%. Ms. Murray stressed this was done to show the BONH's
138	commitment to NHVA. The BONH had hoped to move these funds back into Wealth Management to enable higher
139	returns and allow the BONH to earn fees. Because ICS is FDIC insured, the BONH is unable to lend these dollars to
140	earn interest, and as a result of the dollars sitting in this account, this has cost the BONH to provide the service to



141 NHVA. Ms. Murray pointed to page 27 of the meeting packet. She reviewed the NHVA Net Income vs. Fees table 142 which reflects the total income earned for NHVA and the fees received by the BONH.

143

153

158

164

171

178

187

144 Ms. Murray explained the BONH is committed to assisting the group with investment options. A few questions the 145 Board should consider answering include what is NHVA's risk tolerance; what changes to the investment policy 146 should be made to reflect specific goals and objectives; what will dictate investment parameters; and mandates will 147 there be for performance measurements. In summary, BONH recommended NHVA develop a return objective, 148 income objective, and liquidity objective. Ms. Murray walked the group through the next several slides of their 149 presentation explaining the higher the risk, the higher the returns, and outlined portfolio examples ranging from 150 very conservative to aggressive growth. On page 34 of the packet, Ms. Murray provided a sample investment policy 151 that outlined a time horizon, expected return, and risk profile. Ms. Murray pointed out that the current 2.00% rate 152 for the ICS account is planned to expire at the end of August, and that interest rates are changing.

Mr. Miller would like to draft the investment policy for review at the next Audit Committee meeting scheduled for September 16, 2019, and then discuss it with the Board of Directors meeting on September 25, 2019. Once the policy is approved, the BONH would be able to provide a detailed portfolio and set of investment options. General discussion ensued regarding changes in rates.

Mr. Miller reminded the group that during the RFI process, each respondent was asked to provide comments on the
 NHVA investment policy. These comments can be referenced while working through the development of the revised
 investment policy.

163 V. Administrator Updates

- CY2020 Assessment Process Review and Discussion Mr. Miller directed the group to page 50 of the meeting packet and then walked the group through several slides providing background on the rate setting process highlighting the timeline and re-design accomplishments of 2018 and a listing of significant income and expense events in the past fiscal year. The intent is to bring the proposed assessment rate to the Audit Committee for review and approval on September 16, 2019 and to the Board for review and approval on September 25, 2019.
- 172Mr. Miller referred to the Assessment History / Timeline table on page 56 of the packet. Last year the CDC173replacement credit was budgeted at \$3M but the actual was only \$1.8M. Helms is recommending that this174year's replacement credit be budgeted closer to the \$1.8M for conservative purposes. The Historical Trends175charts were reviewed summarizing the covered lives trend, the carrier percentage contributed to vaccine176expenditures trend, and the changes in investment interest income since Helms took over the177Administration of NHVA.
- 179 Mr. Miller reviewed the eleven CY2020 core rate assumptions on page 62 of the packet. He reminded the 180 group that last year's assessment rate setting process incorporated a lower remittance to the State of NH 181 to begin the process of recoupment of the NHVA funds held by NH DHHS as a result of prior year 182 replacement credits. This will continue again this year. The TRICARE rate cap is expected for now to remain 183 at \$12.47 for CY2020. If the TRICARE rate cap remains steady, it will take approximately 16 quarters to fully 184 recover the \$1,492,489. If the NHVA rate drops, this would accelerate the recoupment. Mr. Miller also 185 noted that TRICARE can change their cap rate and he has inquired with TRICARE that if this were to happen, 186 when and how would it occur.
- 188The group discussed approximate funds still sitting with the DHHS that NVHA plans to recoup. General189discussion ensued about the intent to recoup these dollars over the next few years. Applying a lower CDC



190

191

192

200

207 208

209

210

211

212

213

214

215

226 227

228

229

230

231

232

233

234

235 236

237

238

239

credit amount to the rate process allows a conservative amount of dollars to be recouped without DHHS falling short for vaccine expenditures.

Ms. Daly provided a brief account of historical credits provided by the CDC at the close of each fiscal year. Prior year credit amounts were \$4.3M, \$3.5M, and \$4.2M with last year being \$1.8M, the lowest it has ever been. Ms. Daly explained that much of this fluctuation has to do with purchases made between July 1 and October 1 when the credit is received. The CDC wants each state vaccine program to have one quarter worth of vaccines virtually available on their "shelf" and that is approximately the value of a quarter of vaccines, averaging \$1.5M a month. Ms. Daly advised that the credit is used first for purchasing vaccines when the new fiscal year begins, in this case October 1, 2018.

201General discussion ensued surrounding the rate setting process and how the rates set in September of 2018202determined the anticipated payment to be made to DHHS in June 2020. The actual dollar amount to be203paid each June should be adjusted upon receipt of the actual CDC credit amount with an updated DHHS204payment amount voted upon at the June Board meeting similar to June 2019. Mr. Miller reported we are205on track to fully fund the \$5M reserve fund as of October 1, 2019 and any excess cash beyond the \$5M can206be used for rate stabilization in future years.

Finally, Mr. Miller explained that no assumptions were made for DHHS' request for reimbursement for the DHHS Immunization Section administrative costs. Mr. Miller directed the group to page 67 of the meeting packet in which the DHHS provided table outlines their expense description and corresponding expense amount. The total administrative costs were \$475,367.00 of which they have requested \$285,220.20 be reimbursed by the NHVA. Ms. Daly explained that DHHS' interpretation of the statute is different from Attorney McCue's response last year that these costs are not reimbursable to the State. DHHS would like the Board to reconsider this decision.

- 216 Late Payment Interest Policy Revisions - Mr. Miller reviewed a summary memo and the proposed changes 217 to the drafted Late Payment Interest Policy. This issue is being brought to the Audit Committee as a result 218 of the recent audit, whereby it was determined Helms' interpretation of this policy differed from Carew & 219 Wells interpretation. When Tufts Health Plan voluntarily paid several years of late assessments, they were 220 also charged an interest penalty. Ms. Carew indicated her belief that interest should be calculated 221 beginning the 1st day of late payment (16th day of the due date month), and Helms interpreted this to be on 222 the 15th day after the due date. The policy also currently reads "two weeks" which might be 10 or 14 days 223 and business or calendar days. Helms also administers the assessment process for New Hampshire Health 224 Plan with many of the same carriers as NHVA, and there is a different policy in place for those carriers. Mr. 225 Miller pointed out that there have been no late assessments received since taking over as Administrator.
 - Helms proposed a revised policy for the Audit Committee's consideration (page 73 of the packet). Key points included:
 - Effective January 1, 2020
 - Existing lockbox contract will be canceled and checks will be sent directly to Helms (EFT is still an option as well)
 - ^a Late payment will be based on either the EFT date or the postmark date
 - NHVA will forego pursuit of any interest amount due under \$10 for either situation outlined below:

<u>Filed on Time, Late Payment</u> – If the assessment is filed on time but the payment is received after the due date (45 days after the end of each quarter), interest will be calculated per the Plan of Operation by multiplying the number of days late by 0.000493 by the assessment amount due and invoiced to the assessable entity. The determination of whether a payment is received beyond the



240 241		due date will be made either as the date payment was received electronically, or as of the postmarked data for payments received via bank check.
242		postillarked data for payments received via bank check.
243		Late Filing, Late Payment – If a filing is completed through the NHVA's automated assessment
244		system after the due date (45 days after the end of each quarter), interest will automatically be
245		calculated between the due date and the filing date and will be included on the system generated
246		NHVA invoice. Upon receipt of the payment, NHVA will calculate any interest due between the
247		filing date and the payment received date. Per the Plan of Operation, interest will be calculated by
248		multiplying the number of days late by 0.000493 by the assessment amount due. This will ensure
249		that interest will be collected for all days the payment is late.
250		
251		The policy changes will allow enough time for Helms to educate the carrier community. General discussion
252		ensued and a few clarifying questions were answered.
253		
254	VOTE I	RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously
255		VOTED: To recommend to the Board of Directors at the next Board meeting scheduled for
256		September 25, 2019 to accept the proposed changes to the Late Payment Interest
257 258		Policy to become effective on January 1, 2020.
258 259	VI.	New Business – No new business was identified.
260	VI.	New Business – No new Business was identified.
261	VII.	Adjournment
262	•	Aujournment
263	VOTE	RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously
264		VOTED: To adjourn the Audit Committee meeting at 10:37 am
265		
266		
267		
268	Respe	ctfully submitted by
269	•	k Miller, Helms & Company, Inc.
270		it 13, 2019
271	, 10,600	
272		
272		# # #
215		п п п

Prepared Exclusively

for

NHVA New Hampshire Vaccine Association

Audit Committee

September 16, 2019

Presented by

Dona G. Murray, Vice President and Investment Officer

Arlene C. Folsom, Senior Vice President and Fiduciary Officer



24 New Hampshire Locations ■ BankNH.com ■ 1.603.527.7207



AGENDA September 16, 2019

Summary of Qualifications, Expertise and Strategy	3-4
NHVA Investment Policy Statement edited version NO TRACKING	4 -7
NHVA Investment Policy Statement edited version TRACKING	7-13
NHVA Investment Policy Statement ORIGINAL	14-18



Qualifications, Expertise and Strategy NHVA Audit Committee Meeting September 16, 2019

HISTORY

- Bank of NH was established in 1831 and is the oldest and largest independent bank with headquarters in NH.
- We are a mutual savings bank with no public shareholders and are thus able to implement strategic decisions quickly and with flexibility.
- As a full-service bank, we can offer a wide variety of products in order to provide NHVA with the best returns within the entire bank's product line.

CLIENT BASE

- We manage money for high net worth individuals, non-profit organizations and institutions, as well as retirement plans for businesses.
- Our average relationship size exceeds \$2,000,000, and we have more than \$1 billion under management (including a portfolio we manage for the Bank's holding company).
- Thirteen percent of our Wealth Management relationships are for non-profits.
- The Bank is committed to NH communities, and we routinely contribute to more than 300 organizations yearly.

EXPERTISE

- Bank of NH is uniquely positioned to manage the investment, compliance, risk management and spending needs of our non-profit endowment clients through our team's extensive experience, both collectively now and individually at previous institutions.
- Using world-class research tools and collaboration as a team that possesses broad and varied expertise, our ability to perform the investment management in house is far superior to models used by many competitors. It is particularly important to have this flexibility not only with changing economic conditions, but also for an organization like NHVA with its distinctive investment cash flows.
- We will monitor interest rate and macroeconomic conditions to maximize portfolio yield while managing risk in accordance with your IPS.
- We assist clients with creating, updating, and monitoring investment policy statements that reflect the core values of the organization. We are pleased to assist the NHVA Audit Committee in drafting updated policies suitable to your particular goals.

• As the investment partner of NHVA since 2005, our understanding of your concerns and challenges allows us to provide sound investment advice, critical updates to your Investment Policy Statement when warranted and ongoing guidance for your changing needs.

CLIENT SERVICE

- We generally meet quarterly with our Non-Profit clients to provide reviews of the portfolio as well as economic updates.
- We welcome the opportunity to present to and interact with the NHVA Audit Committee and Board. Sharing of information is important to ensure the investment strategy is appropriate based on current conditions.
- Several Advisors are associated with our relationships to make sure questions and needs get resolved as soon as they arise. We believe strong personal relationships are the keys to a successful partnership. We are proud to be associated with NHVA for more than a decade.
- Bank of NH is pleased to continue working with you on our fee structure. Although most of our clients have a designated fee in place, we will remain flexible because of your unique cash flows as well as the changing economic conditions that we currently face.

STRATEGY

As outlined in the NHVA Investment Policy Statement, the strategy for investing the short-term assets of payer assessments will be to maximize return with minimal risk, using only those instruments with the highest insurance or assumed US government obligation. For longer term assets, some additional risk may be assumed but with the assurance of quality always maintained.

- Our <u>fixed income</u> approach centers on the belief that fixed income plays three important roles: providing liquidity, safety, and yield. Our portfolios are primarily structured with active strategies using a combination of yield curve, sector allocation and duration management to enhance return by taking advantage of changing market conditions. We partner with CreditSights, the major independent credit analysis firm which provides daily reviews of bonds across all data bases.
- We seek to take a fundamental weight of the evidence approach to determine the primary trend of the business cycle and develop <u>asset allocation</u> strategy in accordance with what the economic data and relative valuations are telling us. Technical indicators are used as confirmation of our fundamental view in determining trend and relative strength among asset classes.
- Our approach to <u>equity selection</u> is a bottom up process that incorporates both quantitative and qualitative methods. Our ongoing partnership with Ned Davis Research, a leading provider to institutional managers, focuses on evaluating companies in our equity universe for various fundamental factors and is important in focusing our research team on companies that have superior potential or are at risk at a particular point in time. This screening process occurs on a monthly basis and provides the basis for a more comprehensive review of companies by our team who then take an in depth view of industry and company specific metrics. \
- <u>Funds</u> with outside managers are utilized in one of two circumstances where the portfolio size is not adequate to allow for sufficient diversification with the use of individual securities or to gain exposure to asset classes where a mutual fund or exchange traded fund (ETF) is a more practical alternative than individual securities due to cost or research constraints. BNH's manager selection process incorporates a number of factors including Morningstar rating, performance, manager experience/tenure, expenses and risk. We screen our universe of managers for the factors outlined above to obtain a pool of candidates to evaluate in greater depth. Our research team conducts a more specific review with regard to investment process, performance and fund characteristics. When evaluating investment performance, we look at not only absolute and relative performance, but also consider how we think a fund "should" have performed given its stated objectives.



Investment Policy Statement

I. Purpose

The New Hampshire Vaccine Association's (NHVA) primary purpose is to raise funds, through mandatory assessments paid by private insurance carriers, by Third Party Administrators on behalf of their plans, and by other payers to pay for all vaccines administered to children in the State of New Hampshire who are not eligible for free vaccines under one or more federal programs. NHVA was created in 2002 as a tax-exempt corporation pursuant to New Hampshire State RSA 126-Q.

The purpose of this Investment Policy Statement (IPS) is to establish the responsibility, authority and guidelines for the investment of NHVA's surplus cash. Surplus cash is defined as those funds exceeding the daily operating requirements of NHVA and not immediately required for upcoming financial obligations. The IPS will be reviewed annually and amended as necessary to ensure it remains consistent with the overall objectives of the NHVA and with current financial trends.

II. Investment Objectives and Principles

The major objectives of NHVA's investment program are, in order of priority:

- Safety and preservation of principal by investing in a high-quality, diversified portfolio of securities as described under "Investment Guidelines" below.
- Liquidity of investments that is sufficient to meet NHVA's projected cash flow requirements.
- Conservative market rates of return on invested funds and inflation protection that are consistent with the above stated objectives.
- Maximizing long-term total return including capital appreciation for longer-term assets is not currently a primary goal but may be included upon Audit Committee and Board approval according to the guidelines below.

III. Investment Guidelines

A. <u>Receipts from Payer Assessments:</u>

All securities must mature by June 15

Eligible Investments with Maximums

- United States Government Securities/Treasuries (100%)
- United States Government Sponsored Enterprises (GSEs)
 Those with full faith and credit (75%)
 Those without full faith and credit (50%) and no more than 10% in any one issuer
- Money Market Mutual Funds –Open-end investment company Fund registered under the Investment Company Act of 1940 and rated AAA by at least one major rating agency (S&P, Moody's, or Fitch). The investments of that Fund should comply with the SEC regulations under Rule 2a-7 and maintain a constant net asset value, offer daily liquidity and carry an average weighted maturity that does not exceed 90 days. (100%)
- Bank Deposit and Checking Accounts –guaranteed by FDIC coverage currently set at \$250,000 (100%)
- Bank Deposit and Checking Accounts Beyond FDIC insurance (Board approval required with prudent operating limits set in consideration of the overall economic and operating benefits to NHVA; credit quality of the bank; and overall risk environment.)

B. Longer-Term Investments that may have variable distributions

Eligible investments include the above with addition of *higher-quality corporate debt*.

- At time of purchase, securities must be rated "Baa3/BBB-" or better by at least two agencies (S&P, Moody's, or Fitch)
- No more than 30% of securities shall have a "BBB" rating meaning that 70% shall have ratings of "A3 / A-" or better by at least two agencies
- Maximum of 10% in any one issuer (other than insured or guaranteed instruments)
- No leveraged or structured products
- Advisor shall diversify debt sectors (finance, industrial, energy, etc) except that investments in pharmaceutical and healthcare debt should be limited to 5% of portfolio
- Maturities not to exceed ten years. Securities shall be laddered to provide reasonable cash flow with the average duration not to exceed six years
- Investment manager may employ fixed income mutual funds and/or exchange-traded funds (ETFs) but they must adhere to this IPS in regard to quality and duration of underlying assets.
- Investments may be sold prior to maturity due to changes in credit quality, market condition, or for uncertain capital needs; however, prudence and overall caution must be exercised to minimize any potential losses.

<u>Equity Allocation</u>: Allowable investments may also include an equity allocation at the discretion of the Audit Committee and Board. This would allow for both capital appreciation as well as income. Individual large-cap higher quality stocks and/or mutual funds or exchange-traded funds may be employed with a maximum allocation of 25% of the overall portfolio. Mid-cap, Small-cap and International funds may be included for appropriate diversification with a maximum allocation of 10% of the equity component. The added diversification would be consistent with a still conservative approach to investing and a lower overall risk tolerance but may add possible principal loss, if at least for a shorter time horizon. For assets longer than five years, equity component may grow to a 70% allocation.

At all times NHVA shall hold cash to match the maturity dates with the projected liabilities under NHVA's cash projections. ???

IV. Delegation of Authority and Role of Investment Advisor including Benchmarking, Performance, and Communications

NHVA is authorized to delegate certain responsibilities to professional experts to assist the organization in optimizing an investment strategy aligned with NHVA's objectives. Professionals may include investment management consultants, investment managers, custodians of investments, attorneys, auditors, and any others who may assist NHVA in meeting its responsibilities and obligations to prudently administer the investments of NHVA.

The Audit Committee and Board may delegate investment decisions to a retained professional investment advisor (the "Investment Advisor") who will have full discretion to make all investment decisions for the assets placed under his or her jurisdiction, while observing and operating within all policies, guidelines, constraints, and philosophies as outlined in this statement. Persons responsible for managing and investing the portfolio fund(s) shall act in good faith and with the care an ordinarily prudent person in a like position would exercise under similar circumstances, as set out in UPMIFA and adopted by the State of New Hampshire.

At a minimum, an annual review of the account shall be held by the Investment Manager with the NHVA Audit Committee and/or Board. Performance if relevant, compliance with the policy, and a strategy outlook review shall be discussed. They will also provide educational support on investment considerations as needed. A statement of current holdings and transactions shall be provided at least quarterly to the Audit Committee.

Depending on the structure and duration of the Portfolio, performance evaluation may or may not be required: i.e., if a reasonable percentage of the assets are held for longer than 12 months. If appropriate, the investment performance of the portfolio will be measured and evaluated against one or multiple or a blend of appropriate and commonly accepted performance benchmark indexes and measured over one-, three- and five-year periods. Should any investment fall out of policy or events occur that warrant concern, the Investment Manager must notify NHVA's consultant as soon as possible in writing and present a course of action if necessary.

ENFORCEMENT, REVIEW AND REVISION:

This Policy may be updated from time to time by the Board. DATE ADOPTED: June 9, 2005 SUBSTANTIALLY REWRITTEN: March 9, 2016 AMENDED TO INCLUDE LONGER-TERM INVESTMENT ASSETS: September xx, 2019





Investment Policy Statement

Policy Title:	Investment Policy
Effective Date:	March 9, 2016
Purpose:	Outline of investment policy.

I. Purpose

The New Hampshire Vaccine Association's (NHVA) primary purpose is to raise funds, through mandatory assessments paid by private insurance carriers, by Third Party Administrators on behalf of their plans, and by other payers, to pay for all vaccines administered to children in the State of New Hampshire who are not eligible for free vaccines under one or more federal programs. NHVA was created in 2002 as a tax-exempt corporation pursuant to New Hampshire State RSA 126-Q.

The purpose of this Investment Policy Statement (IPS) is to establish the responsibility, authority and guidelines for the investment of NHVA's surplus cash. Surplus cash is defined as those funds exceeding the daily operating requirements of NHVA and not immediately required for upcoming financial obligations. This investment policy e IPS will be reviewed from time to timeannually and amended as necessary to ensure that it remains consistent with the overall objectives of the NHVA and with current financial trends, while remaining a clear and meaningful document.

II. Investment Objectives and Principles

Persons responsible for managing and investing the portfolio fund(s) shall act in good faith and with the care an ordinarily prudent person in a like position would exercise under similar circumstances, as set out in UPMIFA and adopted by the State of New Hampshire.

The basic major objectives of NHVA's investment program are, in order of priority:

- Safety and preservation of principal by investing in a high--quality, diversified portfolio of securities as described under "Investment Guidelines" below.
- Liquidity of investments that is sufficient to meet NHVA's projected cash flow requirements.
- Conservative market rates of return on invested funds and inflation protection that are consistent with the above stated objectives.
- Maximizing long-term total return including capital appreciation for longer-term assets is not currently a primary goal but may be included upon Audit Committee and Board approval according to the guidelines below.

III. Role of NHVA's Investment Advisor

Generally investment decisions will be delegated by NHVA to a retained professional investment advisor (the "Investment Advisor"). The Investment Advisor shall independently assure compliance with this policy. Additionally, the Investment Advisor will advise NHVA whenever, in the Investment Advisor's independent view, revisions to this Investment Policy seem to be appropriate. The Investment Advisor also shall provide educational support to NHVA's Board on investment considerations periodically and report, not less frequently than quarterly on NHVA's investments. This report shall include a list of current holdings and performance (if applicable). The Investment Advisor shall also certify their continuing compliance with this Investment Policy.

Investment Guidelines

A. Receipts from Payer Assessments:

<u>Maturity</u> –<u>All securities must mature by June 15</u> Individual security maturities should not exceed 60 months (5 years). The weighted average maturity of the portfolio shall not exceed 36 months. No more than 20% of the portfolio will carry maturities beyond 36 months. A maturity or effective maturity by definition shall include puts, announced calls or other structural features which will allow the holder to redeem the investments at a quantifiable price consistent with liquidity, safety and preservation of capital.

Eligible Investments with Maximums

- United States Government Securities/Treasuries (100%) Marketable securities which are direct obligations of the U.S.A., issued by or guaranteed as to principal and interest by the U.S. Government and supported by the full faith and credit of the United States
- United States Government Sponsored Enterprises (GSEs) -<u>Agency Securities</u>
 Those with full faith and credit (75%)
 Those without full faith and credit (50%) and no more than 10% in any one issuer
 Debt securities issued by the Government Sponsored Enterprises (GSEs), Federal-Agencies and certain international institutions which are not direct obligations of the United States, but involve U.S. Government sponsorship and are fully guaranteed by

government agencies or enterprises, including but not limited to:

- Federal Farm Credit Bank (FFCB)
- Federal Home Loan Bank (FHLB)
- Federal Home Loan Mortgage Corporation (FHLMC)
- Federal National Mortgage Association (FNMA)
- Tennessee Valley Authority (TVA)

•____

- Money Market Mutual Funds Shares of an oOpen-end investment company Fund registered under the Investment Company Act of 1940 and rated AAA by at least one major rating agency (S&P, Moody's, or Fitch). The investments of that Fund should comply with the SEC regulations under Rule 2a-7 and maintain a constant net asset value, offer daily liquidity and carry an average weighted maturity that does not exceed 90 days. (100%) The Investment Advisor shall routinely evaluate the Fund's investment portfolio to ensure its compliance with NHVA's Investment Policy.
- Corporate Debt Instruments All commercial paper and other short-term, unsecured promissory notes issued by corporations or financial institutions including but not limited to Master Notes, Medium-Term Notes, Deposit Notes, Eurodollar Notes and Yankee Notes and bonds. Corporate Debt must have either short term or long term ratings. At the time of purchase, a security must have at least 2 short-term ratings of A-1 or P-1 or F1 or higher (S&P, Moody's and Fitch, respectively), or at least 2 long-term debt ratings of A, A2, or A or higher (S&P, Moody's, and Fitch, respectively).
- Bank Deposit and Checking Accounts No limit will be placed on bank deposit or checking accounts as long as they are 100%-guaranteed by FDIC coverage currently set at \$250,000 (100%)

Bank Deposit and Checking Accounts – Beyond FDIC insurance (Board approval required with . Where FDIC limits expire or are otherwise exceeded, the board will set prudent operating limits set in consideration of the overall economic and operating benefits to NHVA; credit quality of the bank; and overall risk environment.)

.

B. Longer-Term Investments that may have variable distributions

Eligible investments include the above with addition of higher-quality corporate debt.

- At time of purchase, securities must be rated "Baa3/BBB-" or better by at least two agencies (S&P, Moody's, or Fitch)
- No more than 30% of securities shall have a "BBB" rating meaning that 70% shall have ratings of "A3 / A-" or better by at least two agencies
- Maximum of 10% in any one issuer (other than insured or guaranteed instruments)
- No leveraged or structured products
- Advisor shall diversify debt sectors (finance, industrial, energy, etc) except that investments in pharmaceutical and healthcare debt should be limited to 5% of portfolio
- Maturities not to exceed ten years. Securities shall be laddered to provide reasonable cash flow with the average duration not to exceed six years
- Investment manager may employ fixed income mutual funds and/or exchange-traded funds (ETFs) but they must adhere to this IPS in regard to quality and duration of underlying assets.

- ——Investments may be sold prior to maturity due to changes in credit quality, market condition, or for uncertain capital needs; however, prudence and overall caution must be exercised to minimize any potential losses.
- •

<u>Equity Allocation</u>: Allowable investments may also include an equity allocation at the discretion of the Audit Committee and Board. This would allow for both capital appreciation as well as income. Individual large-cap higher quality stocks and/or mutual funds or exchange-traded funds may be employed with a maximum allocation of 25% of the overall portfolio. Mid-cap, Small-cap and International funds may be included for appropriate diversification with a maximum allocation of 10% of the equity component. The added diversification would be consistent with a still conservative approach to investing and a lower overall risk tolerance but may add possible principal loss, if at least for a shorter time horizon. For assets longer than five years, equity component may grow to a 70% allocation.

- Diversification Limits To insure adequate sector diversification of the portfolio, the following limits apply:
 - Maximum of 50% of the portfolio will be invested in corporate or other securities.
 - Maximum of 50% will be invested in US Agency or GSE securities including those that carry the full faith and credit of the US Government.
 - Maximum of 25% will be invested in debt issued by banks and financial firms (not including FDIC-insured Certificates of Deposit which have no aggregate limit.)
 - Maximum of 10% will be invested in debt issued by foreigndomiciled firms.
- Issuer Concentration Limits In order to provide adequate issuer risk diversification the following issuer limits apply, based on the portfolio size at the time of purchase:
 - No limit on AAA money funds that otherwise meet policy parameters
 - No limit on US Treasury individual securities
 - Maximum of 10% individual securities backed by any qualifying Agency issuer
 - Maximum of 5% individual securities of any corporate or bank issuer

V. Liquidity Requirements

In order to ensure adequate liquidity for operating purpose and unknown or evolving capital needs, the following requirements should be met:

- At all times NHVA shall hold cash to match the maturity dates with the projected liabilities under NHVA's cash projections. ???
- With the exception of US Treasuries and Agency issuer, any specific issue or debt program should have a minimum issue size of \$240mm.
- Issuers and overall structure should be of high quality and recognized by the market.

The holdings of all NHVA accounts, including all bank and investment accounts, are subject to this policy and may be considered in meeting these liquidity requirements.

VI. Restricted Sectors and Securities

- Investments in issuers in the Pharmaceutical Industry Group are prohibited.
- Investments in issuers in the Healthcare and Healthcare Services Industry Group are prohibited.
- Investments in securities with underlying leverage risk or structured notes are prohibited.
- Investments in Asset Backed securities and Asset Backed Commercial Paper are prohibited.

VII.IV. Delegation of Authority and Role of Investment Advisor including Benchmarking, Performance, and Communications

NHVA is authorized to delegate certain responsibilities to professional experts in various fields to assist the organization to optimize in optimizing an investment strategy aligned with NHVA's objectives. Professionals may include investment management consultants, investment managers, custodians of investments, attorneys, auditors, and any others who may assist NHVA in meeting its responsibilities and obligations to prudently administer the investments of NHVA.

The Audit Committee and Board may delegate investment decisions to a retained professional investment advisor (the "Investment Advisor") who will have full discretion to make all investment decisions for the assets placed under his or her jurisdiction, while observing and operating within all policies, guidelines, constraints, and philosophies as outlined in this statement. Persons responsible for managing and investing the portfolio fund(s) shall act in good faith and with the care an ordinarily prudent person in a like position would exercise under similar circumstances, as set out in UPMIFA and adopted by the State of New Hampshire.

<u>At a minimum, an annual review of the account shall be held by the Investment Manager with</u> <u>the NHVA Audit Committee</u> and/or Board. <u>Performance</u> if relevant, <u>compliance with the policy</u>, <u>and a strategy outlook review shall be discussed</u>. They will also provide educational support on investment considerations as needed. A statement of current holdings and transactions shall be provided at least quarterly to the Audit Committee.

Depending on the structure and duration of the Portfolio, performance evaluation may or may not be required: i.e., <u>-Performance evaluation is more appropriate</u> if a reasonable percentage of

the assets are held for longer than 12 months. If appropriate, the investment performance of the portfolio will be measured and evaluated against one or multiple or a blend of appropriate and commonly accepted performance benchmark indexes and measured over one-, three- and five-year periods. The Investment Advisor shall advise NHVA concerning appropriate benchmarks from time to time and shall also measure its performance against any other benchmarks requested by NHVA.

At a minimum, an annual review of the account shall be held by the Investment Manager with the NHVA Audit Committee. Performance, compliance with the policy, and a strategy outlook review shall be discussed. Should any investment be downgraded, fall out of policy, or events occur that warrant concern, the Investment Manager must notify NHVA's consultant within 48 hoursas soon as possible, in writing to NHVA's Executive Director, Treasurer, and Board Chairperson, and present a course of action if necessary. Investments may be sold prior to maturity due to changes in credit quality, market condition, or for uncertain capital needs; however, prudence and overall caution must be exercised to minimize any potential losses.

VIII. Delegation of Authority

NHVA is authorized to delegate certain responsibilities to professional experts in various fields to assist the organization to optimize an investment strategy aligned with NHVA's objectives. Professionals may include investment management consultants, investment managers, custodians of investments, attorneys, auditors, and any others who may assist NHVA in meeting its responsibilities and obligations to prudently administer the investments of NHVA.

ENFORCEMENT, REVIEW AND REVISION:

This Policy may be updated from time to time by the Board. DATE ADOPTED: June 9, 2005 SUBSTANTIALLY REWRITTEN: March 9, 2016 AMENDED TO INCLUDE LONGER-TERM INVESTMENT ASSETS: September xx, 2019



Investment Policy

Policy Title:	Investment Policy
Effective Date:	March 9, 2016
Purpose:	Outline of investment policy.

I. Purpose

The New Hampshire Vaccine Association's (NHVA) primary purpose is to raise funds, through mandatory assessments paid by private insurance carriers, by Third Party Administrators on behalf of their plans, and by other payers, to pay for all vaccines administered to children in the State of New Hampshire who are not eligible for free vaccines under one or more federal programs. NHVA was created in 2002 as a tax-exempt corporation pursuant to New Hampshire State RSA 126-Q.

The purpose of this Investment Policy is to establish the responsibility, authority and guidelines for the investment of NHVA's surplus cash. Surplus cash is defined as those funds exceeding the daily operating requirements of NHVA and not immediately required for upcoming financial obligations.

This investment policy will be reviewed from time to time and amended as necessary to ensure that it remains consistent with the overall objectives of the NHVA and with current financial trends, while remaining a clear and meaningful document.

II. Investment Objectives and Principles

Persons responsible for managing and investing the portfolio fund(s) shall act in good faith and with the care an ordinarily prudent person in a like position would exercise under similar circumstances, as set out in UPMIFA and adopted by the State of New Hampshire.

The basic objectives of NHVA's investment program are, in order of priority:

- Safety and preservation of principal by investing in a high quality, diversified portfolio of securities as described under "Investment Guidelines" below.
- Liquidity of investments that is sufficient to meet NHVA's projected cash flow requirements.
- Conservative market rates of return on invested funds and inflation protection that are consistent with the above stated objectives.

III. Role of NHVA's Investment Advisor

Generally investment decisions will be delegated by NHVA to a retained professional investment advisor (the "Investment Advisor"). The Investment Advisor shall independently assure compliance with this policy. Additionally, the Investment Advisor will advise NHVA whenever, in the Investment Advisor's independent view, revisions to this Investment Policy seem to be appropriate. The Investment Advisor also shall provide educational support to NHVA's Board on investment considerations periodically and report, not less frequently than quarterly, on NHVA's investments. This report shall include a list of current holdings and performance (if applicable). The Investment Advisor shall also certify their continuing compliance with this Investment Policy.

IV. Investment Guidelines

- <u>Maturity</u> Individual security maturities should not exceed 60 months (5 years). The weighted average maturity of the portfolio shall not exceed 36 months. No more than 20% of the portfolio will carry maturities beyond 36 months. A maturity or effective maturity by definition shall include puts, announced calls or other structural features which will allow the holder to redeem the investments at a quantifiable price consistent with liquidity, safety and preservation of capital.
- 2. Eligible Investments
 - United States Government Securities Marketable securities which are direct obligations of the U.S.A., issued by or guaranteed as to principal and interest by the U.S. Government and supported by the full faith and credit of the United States.
 - United States Government Agency Securities Debt securities issued by the Government Sponsored Enterprises (GSEs), Federal Agencies and certain international institutions which are not direct obligations of the United States, but involve U.S. Government sponsorship and are fully guaranteed by government agencies or enterprises, including but not limited to:
 - Federal Farm Credit Bank (FFCB)
 - Federal Home Loan Bank (FHLB)
 - Federal Home Loan Mortgage Corporation (FHLMC)
 - Federal National Mortgage Association (FNMA)
 - Tennessee Valley Authority (TVA)
 - Money Market Mutual Funds Shares of an open-end investment company Fund registered under the Investment Company Act of 1940 and rated AAA by at least one major rating agency (S&P, Moody's, or Fitch). The investments of that Fund should comply with the SEC regulations under Rule 2a-7 and maintain a constant net asset value, offer daily liquidity and carry an average weighted maturity that

does not exceed 90 days. The Investment Advisor shall routinely evaluate the Fund's investment portfolio to ensure its compliance with NHVA's Investment Policy.

- Corporate Debt Instruments All commercial paper and other short-term, unsecured promissory notes issued by corporations or financial institutions including but not limited to Master Notes, Medium-Term Notes, Deposit Notes, Eurodollar Notes and Yankee Notes and bonds. Corporate Debt must have either short term or long term ratings. At the time of purchase, a security must have at least 2 short-term ratings of A-1 or P-1 or F1 or higher (S&P, Moody's and Fitch, respectively), or at least 2 long- term debt ratings of A, A2, or A or higher (S&P, Moody's, and Fitch, respectively).
- Bank Deposit and Checking Accounts No limit will be placed on bank deposit or checking accounts as long as they are 100% guaranteed by FDIC coverage. Where FDIC limits expire or are otherwise exceeded, the board will set prudent operating limits in consideration of the overall economic and operating benefits to NHVA; credit quality of the bank; and overall risk environment.
- Diversification Limits To insure adequate sector diversification of the portfolio, the following limits apply:
 - Maximum of 50% of the portfolio will be invested in corporate or other securities.
 - Maximum of 50% will be invested in US Agency or GSE securities including those that carry the full faith and credit of the US Government.
 - Maximum of 25% will be invested in debt issued by banks and financial firms (not including FDIC-insured Certificates of Deposit which have no aggregate limit.)
 - Maximum of 10% will be invested in debt issued by foreign-domiciled firms.
- Issuer Concentration Limits In order to provide adequate issuer risk diversification the following issuer limits apply, based on the portfolio size at the time of purchase:
 - No limit on AAA money funds that otherwise meet policy parameters
 - No limit on US Treasury individual securities
 - Maximum of 10% individual securities backed by any qualifying Agency issuer
 - Maximum of 5% individual securities of any corporate or bank issuer

V. Liquidity Requirements

In order to ensure adequate liquidity for operating purpose and unknown or evolving capital needs, the following requirements should be met:

- At all times NHVA shall hold cash to match the maturity dates with the projected liabilities under NHVA's cash projections.
- With the exception of US Treasuries and Agency issuer, any specific issue or debt program should have a minimum issue size of \$240mm.
- Issuers and overall structure should be of high quality and recognized by the market.

The holdings of all NHVA accounts, including all bank and investment accounts, are subject to this policy and may be considered in meeting these liquidity requirements.

VI. Restricted Sectors and Securities

- Investments in issuers in the Pharmaceutical Industry Group are prohibited.
- Investments in issuers in the Healthcare and Healthcare Services Industry Group are prohibited.
- Investments in securities with underlying leverage risk or structured notes are prohibited.
- Investments in Asset Backed securities and Asset Backed Commercial Paper are prohibited.

VII. Benchmarking, Performance, and Communications

Depending on the structure and duration of the Portfolio, performance evaluation may or may not be required. Performance evaluation is more appropriate if a reasonable percentage of the assets are held for longer than 12 months. If appropriate, the investment performance of the portfolio will be measured and evaluated against one or multiple or a blend of appropriate and commonly accepted performance benchmark indexes. The Investment Advisor shall advise NHVA concerning appropriate benchmarks from time to time and shall also measure its performance against any other benchmarks requested by NHVA.

At a minimum, an annual review of the account shall be held by the Investment Manager with the NHVA Audit Committee. Performance, compliance with the policy, and a strategy outlook review shall be discussed. Should any investment be downgraded, fall out of policy, or events occur that warrant concern, the Investment Manager must notify NHVA within 48 hours, in writing to NHVA's Executive Director, Treasurer, and Board Chairperson, and present a course of action if necessary. Investments may be sold prior to maturity due to changes in credit quality, market condition, or for uncertain capital needs; however, prudence and overall caution must be exercised to minimize any potential losses.

VIII. Delegation of Authority

NHVA is authorized to delegate certain responsibilities to professional experts in various fields to assist the organization to optimize an investment strategy aligned with NHVA's objectives. Professionals may include investment management consultants, investment managers, custodians of investments, attorneys, auditors, and any others who may assist NHVA in meeting its responsibilities and obligations to prudently administer the investments of NHVA.

ENFORCEMENT, REVIEW AND REVISION:

This Policy may be updated from time to time by the Board. DATE ADOPTED: June 9, 2005 SUBSTANTIALLY REWRITTEN: March 9, 2016



CY 2020 Assessment Process Discussion

NHVA Audit Committee Meeting September 16, 2019 NH Insurance Department Room 274 **NHVA** New Hampshire Vaccine Association

Contents

- 1. Background
- 2. Historical Trends
- 3. Rate Assumptions and Assessment Rates
- 4. DHHS Information for Assessment Process
- 5. FY2019 Administrative Budget



1. Background

NHVA New Hampshire Vaccine Association

CY2020 Assessment Process Timeline

- July 2019
 - ✓ Data collection for Actual FY2019 and YTD CY2019
 - ✓ Modeling begins
- August 2019
 - ✓ Modeling based upon trends and initial NH DHHS data (8/1)
 - ✓ Concept meeting with the Audit Committee (8/6)
 - ✓ Modeling with final DHHS data received 8/21
- September 2019
 - Review and approval by Audit Committee (9/16)
- September 2019
 - Review and approval by Board of Directors (9/25)
 - Carrier notification of CY2020 rates (9/30)
- October 2019
 - Actual CDC credit received (10/1)

New Hampshire Vaccine Association CY2019 Assessment Process Re-Design Accomplishments

- 1. Simplified the prior assessment process
- 2. Worked to keep the payer assessment aligned with annual vaccine costs in future years
 - Addressed trend reduction in covered lives
 - Addressed trend increase in state vaccine expenditures
 - Reduced payer burden
- 3. Ensured process alignment with RSA 126-Q:4-II and Operations Manual
- 4. Reduced financial risk/exposure to NHVA
 - Managed investment account interest to offset administrative budget
 - As planned, accumulated cash sufficient to fund \$5M Reserve
 - Managed TRICARE claim resolution and ongoing quarterly collections
- 5. Incurred one-time assessment allowance for unbudgeted FY2019 administrative expenses
 - Prior Administrator run out and new Administrator cutover expenses
 - Washington Vaccine Association CY2018 expenses



FY2019 Significant Fiscal Events

- Investment interest income \$222,025
- TRICARE one-time arrearage settlement – \$<u>3,970,307</u>
- TRICARE specific assessment receipt- \$<u>158,485</u>
- Tufts assessment recoupment \$<u>438,771</u>
- Tufts interest recoupment \$<u>131,361</u>

- WVA Expense <u>(\$120,000)</u>
- WVA Final Contribution <u>(\$71,858)</u>
- EBPA refund (<u>\$58,115</u>)
- Minute receivable written off (\$58,270)

NHVA New Hampshire Vaccine Association

Assessment History / Timeline


7

	JAN	FEB	MAR	APR	MAY	JUN	JULY	AUG	SEP	ОСТ	NOV	DEC
CY 2015									Assessment Set CY 2016.			
									\$9.95			_
									DHHS payment \$19,653,132 due 6/30/17	CDC Replacement Credit \$4,377,668		
							SFY 16	SFY 16	SFY 16	SFY 16	SFY 16	SFY 16
CY 2016									Assessment Set CY 2017. \$10.30			
		Assessment Collected			CY 2016 Assessment			CY 2016 Assessment	CY 17 DHHS payment	CDC Replacement Credit	CY 2016 Assessment	<u> </u>
		\$0.14			Collected \$9.95			Collected \$9.95	\$18,819,145 due 6/30/18	\$3,564,068	Collected \$9.95	
	SFY 16	SFY 16	SFY 16	5SFY 16	SFY 16	SFY 16	SFY 17	SFY 17	SFY 17	SFY 17	SFY 17	SFY 1
CY 2017									Assessment Set CY 2018. \$6.70			
		CY 2016 Assessment Collected \$9.95			CY 2017 Assessment Collected \$10.30	CY 2016 Assessment Paid to DHHS \$19,653,132 6/30/17		CY 2017 Assessment Collected \$10.30	CY2018 DHHS payment \$9,234,656 due 6/30/19	CDC Replacement Credit \$4,282,619	CY 2017 Assessment Collected \$10.30	
	SFY 17	SFY 17	SFY 17	7SFY 17	SFY 17		SFY 18	SFY 18	SFY 18	SFY 18	SFY 18	SFY 18
CY 2018						\$5,515,270			Assessment Set CY 2019 \$6.47			
		CY 2017 Assessment			CY2018 Assessment	CY 2017 Assessment Paid		CY2018 Assessment	CY 2019 DHHS expected	CDC Replacement Credit	CY2018 Assessment	
		Collected \$10.30			Collected \$6.70	to DHHS \$18,819,145 6/30/18		Collected \$6.70	payment due 6/30/20 \$11,751,393	\$1,856,544	Collected \$6.70	
	SFY 18	SFY 18	SFY 18	3SFY 18	SFY 18	SFY 18 DHHS Reports Balance Forward \$12,979,343	SFY 19	SFY 19	SFY 19	SFY 19	SFY 19	SFY 19
CY 2019									Assessment Set CY 2020 \$6.80			
		CY2018 Assessment			CY 2019 Assessment	CY 2018 Assessment Paid		CY 2019 Assessment	CY 2019 DHHS expects	CDC Replacement Credit	CY 2019 Assessment	
		Collected \$6.70			Collected \$6.47	to DHHS \$9,234,656 6/30/19		Collected \$6.47	\$16,570,000 due 6/30/21	\$1,800,000 10/01/19	Collected \$6.47	
	SFY 19	SFY 19	SFY 19	9SFY 19	SFY 19	SFY 2019 DHHS Reports Balance Forward \$6,722,034	SFY 20	SFY 20	SFY 20	SFY 20	SFY 20	SFY 20
CY 2020									Assessment Set CY 2021 \$6.95			
		CY 2019 Assessment			CY 2020 Assessment	CY 2019 Assessment to		CY 2020 Assessment	DHHS payment	CDC Replacement Credit	CY 2020 Assessment	
		Collected \$6.47			Collected \$6.80	Pay to DHHS \$11,751,393 6/30/20		Collected \$6.80	\$14,790,000 due 6/30/22	\$1,800,000 10/01/20	Collected \$6.80	
	SFY 20	SFY 20	SFY 20	DSFY 20	SFY 2020	SFY 2020 DHHS Reports Balance Forward \$0.00	SFY 21	SFY 21	SFY 21	SFY 21	SFY 21	SFY 21
CY 2021									Assessment Set CY 2022 \$7.00			
		CY 2020 Assessment			CY 2021 Assessment	CY 2020 Assessment Paid		CY 2021 Assessment	DHHS payment	CDC Replacement Credit	CY 2021 Assessment	
		Collected \$6.80			Collected \$6.95	to DHHS \$16,570,000 6/30/21	20	Collected \$6.95	\$15,480,000 due 6/30/23	\$1,800.000 10/01/21	Collected \$6.95	
	SFY 21	SFY 21	SFY 21	SFY 21	SFY 21	SFY 2021 DHHS Reports Balance Forward \$0.00		SFY 22	SFY 22	SFY 22	SFY 22	SFV 2




2. Historical Trends

New Hampshire Vaccine Association Shrinking Assessed Lives and Variability in Assessed Rate




Source: NHVA KidsVax[®] reconciliation spreadsheet, 09-06-2018; NHVA Data August 2019 Note: Total Assessed Lives reflects CY2019 Tufts recovery activity and EBPA refund activity

NHVA New Hampshire Vaccine Association Increasing State Vaccine Expenditures and **Stability in Payer Proportion**



NHVA New Hampshire Vaccine Association Vaccine Association



Association



3. Rate Assumptions and Assessment Rates

NHVA New Hampshire Vaccine Association

CY2020 Core Rate Assumptions (as of September 8, 2019)

- 1. Board commitment to keeping rates stable in future years (~\$6.50-\$8.00)
- 2. NHVA funds held by NH DHHS will be recovered in June CY2020 for the second year in a row; the model will recover CDC credit the year following the receipt
- 3. Total assessed lives is declining by 0.1% per year and will continue
- 4. A reserve of 10% will be taken of the total non-Federal program cost for the succeeding year (RSA 126-Q:4 II.(c))
- The TRICARE cap rate of \$12.47 will continue in CY2020 and TRICARE's \$1,492,489 future, specific assessment receivable will be paid down in full in 16 quarters at the current rate of \$12.47
- The percentage paid by the carriers is 59.6% using trended costs
- NHVA will not recover the prior, outstanding Minuteman receivable (\$58,270 fully reserved as of 6/30/18)

- The CDC's annual credit on October 1, 2019 will be no more than last year's \$1.9M and the model will recover the CDC credit with the payment to DHHS planned June 2021
- 9. NHVA will fully fund the \$5M reserve fund as of October 1, 2019 and any excess cash beyond the \$5M will be used for rate stabilization in future years
- 10. No assumption made for late payment interest assessments
- 11. No assumption made for reimbursement of NH DHHS Immunization Section administrative costs
- 12. Interest rate assumptions for cash on hand assume decreases from 2.0% to 1.00% by 9/30/2020

NHVA New Hampshire Vaccine Association

Cash Flow / Reconciliation / Rates

[-			_		
		MODEL		MODEL			FUTURE YEARS					
Description	CY19 Annual	SFY19 for	CY20 Annual	Draft SFY20		Annual		Proje	ected A	Assessmer	it Rate - 4 years	
	Adjustment	CY19 Rate	Adjustment	for CY20		Adjustment		0.5%				
	Factors		Factors	Rate		Factors		SFY 2021	SF	Y 2022	SFY 2023	SFY 2024
4 Drive Veen ACTUAL Auto Tetel Funder diture is la success from Act CEV 40	4 7 40/	¢ 00.007.040	2.1%	\$ 28.844.638		2.1%	¢	07.054.404	¢ 0	0 505 404	¢ 00.444.077	¢ 00 700 00/
4 Prior Year ACTUAL Avg Total Expenditure + Increase from Act SFY 18	1.74%	\$ 26,837,646	2.1%	• • • • • • • •		2.1%	\$	27,951,401	<u>م</u> ۲	8,525,494	\$ 29,111,377	\$ 29,709,292
Provision for Vaccine Utilization Increase + Vaccine Cost Increase Subtotal		Actual SFY19		DHHS Trend Proj								
Less: Estimated VFC and Estimated NH General Fund												
Less: Estimated VFC and Estimated NH General Fund												
4 Prior Year ACTUAL Average % Paid by Insurers		57.72%		64.04%		59.70%		59.70%		59.70%	59.70%	59.70%
		Actual SFY19		DHHS Trend Proj								
Amount NHVA to pay DHHS (projected) Before Offsetting DHHS Surplus		\$ 15,490,000		\$ 18,470,000			\$	16.690.000	\$ 1	7.030.000	\$ 17,380,000	\$ 17.740.000
		• • • • • • • • • •								,,	· /···/·	* / -/
Normalized Administrative Expenses		\$ 144,727	0.00%	\$ 142,700		3.00%	\$	142,700	\$	146,981	\$ 151,390	\$ 155,932
Provision for One-Time Expenditures		\$ 174,359		\$-			\$	-	\$	-	\$-	\$-
Admin % of Total Vaccine Costs		1.19%		0.49%				0.51%		0.52%	0.52%	0.52%
Total Assessment to be Raised - Before "Cushion"		\$ 15,809,086		\$ 18,612,700			\$	16,832,700	\$ 1	7,176,981	\$ 17,531,390	\$ 17,895,932
	40.000/	¢ 4 500 000	40.00%	¢ 4.004.070		40.00%	¢	4 000 070	¢	4 747 000	¢ 4 750 400	¢ 1 700 500
Apply Cushion ("Reserve") 10% per RSA 126-Q:4 II.(c) Actual Cushion ("reserve")	10.00%	\$ 1,580,909	10.00%	\$ 1,861,270		10.00%	\$	1,683,270	Þ	1,717,698	\$ 1,753,139	\$ 1,789,593
		¢ (054.040)		¢ (007.754)			¢	(404.074)	¢	(470.050)	¢ (400 507)	¢ (404 505
Investment Earnings		\$ (351,842)		\$ (267,751)			\$	(191,271)	Ф	(173,358)	\$ (169,587)	\$ (161,595
Grand Total Assessment to be Raised - Before DHHS Offset		\$ 17,038,153		\$ 20,206,219			\$	18,324,699	¢ 1	8 721 322	\$ 19,114,942	\$ 10 523 030
Grand Total Assessment to be Maised - Delote Drints Offset		φ 17,030,133		\$ 20,200,219			φ	10,324,033	ψι	0,721,322	\$ 13,114,342	ψ 19,525,950
Final Assessment to be Raised												
Less: Q1 Assessments Collected in May		\$ (3,235,518)		\$ (3,397,741)			\$	(3,469,835)	\$ (3.491.923)	\$ (3,489,051)	\$ (3.685.392
		· (-,,,		· (•	(-,,,		, - ,,	• (-,,,	
Estimated Assessable Lives	-1.30%	166,693	-0.10%	166,556		0.1%		166,693		166,830	166,967	167,105
Rate Based on Proposed Cash Flow Outcomes												
Q1 - Q3		\$ 10.30		\$ 6.70			\$	6.47		6.80		
Q4 Collected in May following at new rate		\$ 6.70		\$ 6.47			\$	6.80		6.95		
Projected Year End Cash Balance		Actual 6/30/19		Projected 6/30/20				ojected 6/30/21			Projected 6/30/23	
Beginning Balance	As of 6/30/2018			\$ 12,220,200	Pro	j Year Beg =>	\$	14,017,882			\$ 10,888,798	
Projected Cash Received from Assessments - FY basis		\$ 17,796,406		\$ 13,428,274			\$	13,928,941			\$ 14,288,821	
Projected Interest Received		\$ 351,842		\$ 267,751			\$	191,271		173,358		\$ 161,595
Total Receipts		\$ 18,148,248		\$ 13,696,025			\$	14,120,212	\$ 1	4,398,785	\$ 14,458,409	\$ 14,352,146
Projected Gross Vaccine Costs after deducting VFC and NH credits		\$ 19,149,829		\$ 15.491.964			\$	18,470,000	\$ 1	6 690 000	\$ 17,030,000	\$ 17 380 000
Less: Carryforward DHHS unspent funds		\$ (9,915,173)		\$ (3,740,571)			\$	(1,900,000)			\$ (1,900,000)	
Net cash payments due DHHS		\$ 9,234,656		\$ 11,751,393			\$				\$ 15,130,000	
Cash Paid for Administrative Expenses		\$ 390,876		\$ 146,950			\$	141,900		146,181		\$ 155,132
Total Disbursements		\$ 9.625.532		\$ 11,898,343	1		\$	16.711.900			\$ 15,280,590	
Projected Ending Balance	Actual 6/30/19	+ -//		\$ 14,017,882	Proi	Year Ending =>		11,426,194			\$ 10,066,617	
, , ,		Actual 6/30/19		Projected 6/30/20		j		ojected 6/30/21			Projected 6/30/23	
Projected Q1 Assessments collected in May	\$ 3,315,354	\$ 3,235,518		\$ 3,397,741			\$	3,469,835			\$ 3,489,051	
Projected Year end Cash Reserve - Target \$5.0M	\$ 382,130	\$ 8,984,682		\$ 10,620,141			\$	7,956,360				\$ 5,098,238
		\$ 12,220,200		ψ 10,020,141							ψ 0,011,000	





4. DHHS Information for Assessment Process

New Hampshire Vaccine Association Vaccine Content Vaccine Discrete Vaccine Association

			cast for SFY 20																				
	New	/ Hampsh	ire Immunization	Program																			
																		SFY 20 Tota	al Projected				
Y 19			une 30, 2019										SFY 19 Total Cost					Co	ost				
		18 Price	4-1-01-		0.1		0.1.1.1.		4th atr	2019 Price		Total		.5%	SFY 2019		2019 Price Per Doses						
VACCINE		r Doses Cost	1st Qtr Totals	Total	2nd qtr totals	Total	3rd qtr totals	Total	4th qtr totals	Per Doses Cost	Total	ordered in SFY 19		.5% wastage	+.5%	Roundings	Cost				Private Pr	inat	
T	\$	51.56	10 \$	515.60	11 \$	567.16	18 \$	928.08	15		\$ 819.45	54	\$ 2.830.29	wastage	+.5%	60		3 6	3.277.80	¢	54.63 \$	2.964.77	
СТНІВ	\$	9.23	6190 \$	57,133.70	6325 \$	58.379.75	6070 \$	56,026.10	5485		\$ 51,997.80	24070		120		24200			229,416.00	s	16.51 \$	399,382.68	
IBERIX	\$	9.65	280 \$	2,702.00	330 \$	3.184.50	220 \$	2,123.00	270		\$ 2.554.20	1100		6	1106	1100			10.406.00	Š	10.85 \$	11.994.68	
APTACEL	\$	17.61	370 \$	6,515.70	410 \$	7,220.10	260 \$	4,578.60	410	\$ 18.07	\$ 7,408.70	1450	\$ 25,723.10	7	1457	1500	\$ 18.07	7 \$	27,105.00	S	30.84 \$	44,941.59	
NFANRIX	\$	18.19	1970 \$	35,834.30	2010 \$	36,561.90	1650 \$	30,013.50	1860	\$ 18.67	\$ 34,726.20	7490	\$ 137,135.90	37	7527	7500	\$ 18.67	7 \$	140,025.00	\$	24.71 \$	186,003.29	
NGERIX B	\$	14.03	1770 \$	24,833.10	1940 \$	27,218.20	2020 \$	28,340.60	3620			9350		47	9397	9400			150,588.00	\$	23.72 \$	222,890.91	
ECOMBIVAX HB		12.30	3030 \$	37,269.00	3640 \$	44,772.00	2930 \$	36,039.00	1520			11120		56	11176	11200			137,760.00	\$	23.95 \$	267,655.62	
AVRIX	\$	19.58	8990 \$	176,024.20	8180 \$	160,164.40	7830 \$	153,311.40	8840			33840		169	34009	34000			697,680.00	\$	32.89 \$	1,118,562.59	
AQTA	\$	19.29	680 \$	13,117.20	740 \$	14,274.60	550 \$	10,609.50	610		\$ 11,992.60	2580		13	2593	2600			51,116.00	\$	32.66 \$	84,684.11	
POL	\$	13.30	680 \$	9,044.00	690 \$	9,177.00	570 \$	7,581.00	580	+		2520		13	2533	2500	• • • • •		33,875.00	5	33.53 \$	84,918.08	
	\$ \$	40.19 39.57	2790 \$ 640 \$	112,130.10 25.324.80	2850 \$ 780 \$	114,541.50 30.864.60	2050 \$ 670 \$	82,389.50 26.511.90	2510 730		\$ 103,688.10 \$ 29.681.80	10200 2820		51 14	10251 2834	10300			425,493.00 113.848.00	3 C	52.12 \$ 53.13 \$	534,282.12 150.575.73	
M-M-R II	ֆ Տ	21.05	3320 \$	69.886.00	3210 \$	67.570.50	3000 \$	63,150.00	4250		\$ 90,185.00	13780		69	13849	13800			292.836.00	ŝ	75.04 \$	1.039.221.46	
ROQUAD	ֆ Տ	125.11	3530 \$	441.638.30	3070 \$	384.087.70	2960 \$	370.325.60	3700		\$ 90,185.00	13780		66	13326	13300			747.620.00	ŝ	214.37 \$	2.856.758.93	
PEDIARIX	\$	57.97	4110 \$	238.256.70	4410 \$	255.647.70	4610 \$	267.241.70	3530			16660		83	16743	16700			986.135.00	ŝ	79.15 \$	1.325.232.20	
PENTACEL	\$	58.33	5190 \$	302,732.70	4920 \$	286,983.60	5235 \$	305,357.55	5215			20560		103		20700			229,994.00	ŝ	96.14 \$	1,986,521.59	
NEUMOVAX 23		53.11	55 \$	2,921.05	41 \$	2,177.51	23 \$	1,221.53	24	• • • •	\$ 1,351.20	143		1	144	160			9,008.00	ŝ	100.19 \$	14,398.81	
REVNAR 13 TM	\$	131.77	11290 \$	1,487,683.30	11690 \$	1,540,391.30	11430 \$	1,506,131.10	10800	\$ 137.01	\$ 1,479,708.00	45210	\$ 6,013,913.70	226	45436	45400	\$ 137.01	1\$6,	220,254.00	\$	180.05 \$	8,180,760.80	
ROTARIX	\$	92.85	1270 \$	117,919.50	1540 \$	142,989.00	1500 \$	139,275.00	1260		\$ 119,309.40	5570		28	5598	5600			530,264.00	\$	120.95 \$	677,059.96	
ROTATEQ	\$	70.49	5940 \$	418,710.60	5910 \$	416,595.90	5990 \$	422,235.10	5500		\$ 387,695.00	23340		117		23500			656,515.00	\$	82.89 \$	1,944,325.86	
/ARIVAX	\$	98.24	3440 \$	337,945.60	3140 \$	308,473.60	3050 \$	299,632.00	3720	\$ 104.09	\$ 387,214.80	13350	\$ 1,333,266.00	67	13417	13400	\$ 104.09	9\$1,	394,806.00	\$	129.30 \$	1,734,785.78	
dele e e est																					\$	-	
Adolescent	¢	20.00	090 €	20 272 20	770 €	22 705 20	710 \$	21 021 00	880	¢ 04.75	¢ 27.040.00	2240	¢ 102.020.40	17	3357	2400	¢ 04.70		107.050.00	6	45 50 C	-	
BEXSERO	\$ \$	30.89 129.06	980 \$ 4907 \$	30,272.20 633.297.42	770 \$ 2168 \$	23,785.30 279.802.08	2165 \$	21,931.90 279.414.90	2725		\$ 27,940.00 \$ 369.183.00	3340 11965		60	12025	3400			107,950.00	3 e	45.50 \$ 170.75 \$	152,729.85 2.053.238.87	
BOOSTRIX	\$	31.37	3770 \$	118,264.90	2980 \$	93,482.60	2080 \$	65,249.60	2920		\$ 94,140.80	11750		59	11809	11800			380,432.00	9 6	41.19 \$	486,402.41	
GARDASIL9	\$	168.10	10340 \$	1,738,154.00	8280 \$	1,391,868.00	6180 \$		7150			31950		160	32110	32100			718,294.00	s	217.11 \$	6,971,347.82	
MENACTRA	\$	91.81	8710 \$	799,665.10	6305 \$	578,862.05	4365 \$	400,750.65	5350			24730		124	24854	24900			326,905.00	ŝ	122.31 \$	3,039,849.93	
IENVEO	\$	92.10	1170 \$	107,757.00	890 \$	81,969.00	535 \$	49,273.50	790			3385		17	3402	3400			322,456.00	ŝ	130.75 \$	444,801.69	
ENIVAC	\$	20.05	89 \$	1,784.45	95 \$	1,904.75	72 \$	1,443.60	74	\$ 20.60	\$ 1,524.40	330	\$ 6,657.20	2	332	300	\$ 20.60	0 \$	6,180.00	\$	33.83 \$	11,219.72	
RUMENBA	\$	104.79	680 \$	71,257.20	270 \$	28,293.30	230 \$	24,101.70	320	\$ 108.95	\$ 34,864.00	1500	\$ 158,516.20	8	1508	1500	\$ 108.95	5 \$	163,425.00	\$	133.62 \$	201,432.15	
			\$	7,418,589.72	\$	6,391,809.60	\$	5,694,045.61			\$ 6,355,012.55		\$ 25,859,457.48					\$ 26,	739,423.80		\$	36,228,943.99	
			1	1																			
			/																				
			4.1.01		Or dista		Oral ata		Ath ata							Commited State Do							
nfluenza Vaccine			1st Qtr Totats		2nd qtr totals		3rd qtr totals		4th qtr totals				Spent this Season			nfluenza ordered 2 or Next Season		er					
ANOFI.25 Baby f	¢	15.11	9210 \$	139.163.10	4590 \$	69,354.90	1900 \$	28,709.00	380	\$ 15.11	\$ 5.741.80	16080				63000		E @	866.250.00	e	18.31 \$	1 152 520 00	SANOFI.5 Kid flu
	Ф \$	15.11	19630 \$	296.609.30	4590 \$	243,271.00	3310 \$	50,014.10	290			39330				51000			688.500.00	s	16.82 \$		GSK.5 Kid fluari
	ֆ Տ	13.50	35220 \$	475.470.00	27330 \$	412,956.30	0 \$		290			62550				35000			472,500.00	s	16.82 \$		GSK.5 Flulaval
	\$	13.50	2300 \$	31.050.00	18140 \$	274.095.40	6660 \$	89.910.00	800			27900				400			6.220.00	s	24.05 \$.5 Flucelvax
	\$	14,43	10 \$	144.30	60 \$	906.60	0000 \$	-	000			70				3800			71.744.00	ŝ	23.70 \$	90,060.00	
5 Flucelvax	Ŧ		S-	> 942,436.70	¢	1,000,584.20	\$	168,633.10	Ű		\$ 20,923.70		\$ 2,059,330.20			2500			105,214.00		Ś	2,699,730.00	
5 Flucelvax		-				.,		,					,,			\$ (45.883.80)	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	, , _,				_,,	
Pediatric vaccine															~	ifference							
Pediatric vaccine plus														_	C	linerence				_			
Pediatric vaccine plus influenza											\$ 6,375,936.25		\$ 27,918,787.68					\$ 28	844,637.80	Estimated cos	t of vaccir ¢	38,928,673.99	-26%
Pediatric vaccine plus		4		8 361 026 42	•	7 392 393 80	0	5 862 678 71					÷ 21,010,101.00					÷ 20,	012,007.00	Loundtou COS	τo vacon φ	55,520,010.99	2070
Pediatric vaccine plus influenza		/	→ s	8,361,026.42	\$	7,392,393.80	\$	5,862,678.71			\$ 0,373,830.23	U								on private mar	ket		
Pediatric vaccine plus influenza			> \$	8,361,026.42	\$	7,392,393.80	\$	5,862,678.71			φ 0,373, 3 30.23							<u> </u>	/	on private mar	ket		
Pediatric vaccine plus influenza			→ s	8,361,026.42	\$	7,392,393.80	\$	5,862,678.71			φ 0,373, 3 30.23	l		VEC Estima	ated Vaccin	- Funde Contributio	in .	\$ (10)	097 211 00			Amount is subject	to change
Pediatric vaccine plus influenza equals			→ \$	8,361,026.42	\$	7,392,393.80	\$	5,862,678.71			φ 0,313,330.23					e Funds Contribution	n		097,211.00)	This amount	is for FFY18	3. Amount is subject	
Pediatric vaccine plus influenza equals			→ \$	8,361,026.42	\$ 	7,392,393.80	\$	5,862,678.71			\$ 0,373,330.23					e Funds Contributio Contribution	'n		097,211.00) 274,000.00)	This amount Final amount	is for FFY18 will be avai	able in October 201	
Pediatric vaccine plus influenza equals pdated 7/30/19		ictributed			\$	7,392,393.80	\$	5,862,678.71			\$ 0,373,330.23			Estimated S	State Funds		'n	\$ (274,000.00)	This amount Final amount	is for FFY18 will be avai		
Pediatric vaccine plus influenza equals pdated 7/30/19	es di	istributed			sport	7,392,393.80	\$	5,862,678.71			φ 0,510,500.20			Estimated S	State Funds	Contribution	n	\$ (<u>\$ 18,</u>		This amount Final amount	is for FFY18 will be avai	able in October 201	
Pediatric vaccine plus influenza equals pdated 7/30/19 .ctual TOTAL dos			taken from mont	hly Spend Plan Ré							φ 0,573,530.23			Estimated S NHVA Estin Unspent NH	State Funds nated Cost IVA revenue	Contribution e from prior SFYs	'n	\$ () <u>\$ 18,</u> TBD	274,000.00) 473,426.80	This amount Final amount SFY20 state	is for FFY18 will be avait budget is no	able in October 201 ot yet approved.	9.
Pediatric vaccine plus influenza equals pdated 7/30/19 wctual TOTAL dos pril 2019 CDC Prices			taken from mont	hly Spend Plan Re	s/vfc/awardees	/vaccine-managemen	t/price-list/2018/.	2018-04-01.html			φ 0,573,530.23			Estimated S NHVA Estin Unspent NH NHVA shan	State Funds nated Cost IVA revenue e of replace	Contribution e from prior SFYs ment credits		\$ () <u>\$ 18,</u> TBD \$ (3,)	274,000.00) 473,426.80 500,000.00)	This amount Final amount SFY20 state 4-year avera	is for FFY18 will be avait budget is no ge. We will	able in October 201 ot yet approved.	9.
Pediatric vaccine plus influenza			taken from mont	hly Spend Plan Re	s/vfc/awardees		t/price-list/2018/.	2018-04-01.html			9 U,010,000,20			Estimated S NHVA Estin Unspent NH NHVA shan DHHS Prog	State Funds nated Cost IVA revenue e of replace gram Admini	Contribution e from prior SFYs		\$ () <u>\$ 18,</u> TBD \$ (3,)	274,000.00) 473,426.80 500,000.00) 285,220.00	This amount Final amount SFY20 state 4-year avera See workshe	is for FFY18 will be avail budget is no ge. We will eet e for deta	able in October 201 ot yet approved.	9. on October 1st.

NHVA New Hampshire Vaccine Association

DHHS Tab D 08-21-2019

				SFY19	SFY18	SFY17	SFY16	SFY15	SFY14	SFY13	SFY12	SFY11	SFY10	SFY09	SFY08
		Sourc	ce	2018/2019	2017/2018	2016/2017	2015/2016	2014/2015	2013/2014	2012/2013	2011/2012	2010/2011	2009/2010	2008/2009	2007/2008
Actual Total exp		4+7		\$ 26,837,646	\$ 26,377,918	\$ 24,657,418	\$ 24,741,423	\$ 26,092,637	\$ 20,945,469	\$ 21,918,042	\$ 21,707,838	\$ 21,961,081	\$ 28,121,414	\$ 17,820,721	\$ 25,454,043
VFC	1		Mon Rpt	\$ 11,071,713				\$ 8,570,780				\$ 7,549,887	\$ 11,624,679		
317 - not used for children	2	1 1	Mon Rpt	not provided	not provided	not provided	not provided	not provided	not provided	\$ 156,375			\$ 1,676,638		\$ 2,219,343
State Funds	3	St. Ap	p(5178-513)	\$ 273,969	\$ 293,211	\$ 392,339	\$ 302,821	\$ 206,762	\$ 460,501	\$ 482,467	\$ 320,494	\$ 492,762	\$ 573,306	\$ 213,821	\$ 422,798
TOTAL GOV'T EXPENDED	4	1+2+	+3	\$ 11,345,682	\$ 10,622,944	\$ 11,652,089	\$ 9,497,360	\$ 8,777,542	\$ 8,531,344	\$ 8,190,532	\$ 8,956,773	\$ 8,763,261	\$ 13,874,623	\$ 5,952,189	\$ 11,230,599
beg balance	5	State	e Approp	\$ 12,979,343	\$ 9,915,172	\$ 3,267,370	\$ (1,107,266)	\$ 3,797,531	\$ 207,631	\$ 3.042.624	\$ 6,102,932	\$ 7,039,214	\$ 12,293,560	\$ 7,759,278	\$ 4,919,231
revenue from NHVA*	6		e Approp	\$ 9,234,656				\$ 12,410,298			1 ., . ,	\$ 12,261,538		\$ 16,402,814	
Vaccine Insurers expended	7	State	e Approp	\$ 15,491,964	\$ 15,754,974	\$ 13,005,330	\$ 15,244,063	\$ 17,315,095	\$ 12,414,125	\$ 13,727,510	\$ 12,751,065	\$ 13,197,820	\$ 14,246,791	\$ 11,868,532	\$ 14,223,444
vear end encumbered	8	Chata		ć 214.014	ć 4 110 250	ć 2.012.027	¢ 5 2 C0 C 41	ć (1.217.010)	¢ 4.022.400	ć 2,270,207	¢ 2.409.054	ć 4 102 155	ć 2.059.211	¢ 2,020,050	¢ 5.020.024
/	9	1 1	e Approp	\$ 214,014				\$ (1,217,018)			\$ 3,498,954	\$ 4,183,155 \$ 1.919.776		\$ 2,636,659 \$ 9.656.901	\$ 5,038,824
year end cash TOTAL BAL FORWARD	10	(5+6)	e Approp	\$ 6,508,021 \$ 6,722,035				\$ (1,107,266)	\$ 1,124,869 \$ 3,797,531	\$ (2,070,756) \$ 207.631	\$ (456,331) \$ 3.042.624	\$ 6,102,932	1 / /	\$ 9,656,901	\$ 2,720,454 \$ 7.759.279
TOTAL BALTONWARD	10	(3+0)	<i>ij-i</i>	\$ 0,722,033	\$ 12,575,345	\$ 5,515,172	\$ 3,207,370	\$ (1,107,200)	\$ 3,737,331	\$ 207,031	5 5,042,024	\$ 0,102,532	\$ 7,035,213	\$ 12,295,500	\$ 1,155,215
CDC end of fiscal year credit	11	CDC	Vtracks	\$ 1,856,544	\$ 4,282,619	\$ 3,564,068	\$ 4,377,668	not provided	not provided	not provided	N/A	N/A	N/A	N/A	N/A
Reimbursement from Providers and Excise Tax	6A	State	e Approp			\$ 19,863	\$ 13,916	\$ 37,311	\$ 29,970	\$ 119,460					
Added into this account															
		Sourc	ce: From Beth	Daly 603-271-49	27 on August 21, 20	19									
Note: NHVA as % of total budget				57.729	59.73%	52.74%	61.61%	66.36%	59.27%	62.63%	58.74%	60.10%	50.66%	66.60%	55.88%

New Hampshire Vaccine Association 08-01-2019

			Amount
Expense	Description	Total Cost	Requested from
Vaccine Ordering Management Syst	Mechanism for providers to order vaccines online and for the program to track		
	vaccines, generate reports on administration, wastage, etc.	\$167,762.00	\$100,657.20
/accine Accountability Coordinator	Responsible for the purchase and distribution of all vaccines within the program.		
	This position manages Vaccine For Children (VFC), 317, and state/local vaccine		
	funding. This individual tracks vaccine inventory, vaccine distribution and		
	administration, vaccine wastage, trends, all of which informs forecasting. This		
	postion plays a key role during the influenza season by closely tracking flu vaccine		
	expenditures and distribution to ensure the vaccines are in the right quantities and		
	the right location, allowing for successful clinic outcomes. This position works		
	directly with the Public Health Regions to plan vaccine distribution for Pandemic		
	Exercises or vaccine-preventable disease outbreaks. The position collaborates with		
	the Immunization Information System (IIS), Vaccine Data Coordinator to provide conducts vFC site visits with enrolled nearth care providers. Conducts on-site	\$88,273.00	\$52,963.80
/accine Quality Specialist	training for new Vaccine Managers; offers educational programs related to overall		
	vaccine management, including storage and handling. Reviews all health care		
	provider vaccine management (including emergency) plans; coordinates annual		
	vaccine provider enrollment process, reviewing all health care provider	\$79,666.00	\$47,799.60
Program Specialist II	Under the direction of the Vaccine Accountability Coordinator, adhering to the		
	standards of vaccine accountability and the VFC Operations Policy & Procedures,		
	this position is responsible for working in the Vaccine Ordering Management		
	System (VOMS/IIS); working with health care provider vaccine ordering-related		
	documents, including vaccine orders, temperature logs and applicable reports. This		
	position works directly with health care providers and staff related to overall	\$71,916.00	\$43,149.60
echnical Support Specialists (2)	This positions operates the technical support Help Desk for the Vaccine Ordering		
	Management System. Interacts with VTrckS (CDC vaccine ordering system) as it		
	relates to the ExIS connection (VOMS) that passes information between the two		
	systems. Works with both systems to assure data quality and vaccine ordering		
	accountability. Works directly with medical health care provider practices to assure		
	education for staff. Develops interoperability processes to inform evidence-based		
	strategies.	\$67,750.00	\$40,650.00
		\$475,367.00	\$285,220.20
	nat approximately 60% of the vaccines that the the New Hampshire Immunization Sec		



5. FY2020 Administrative Budget

New Hampshire Vaccine Association FY2020 Administrative Budget – Adopted by Board June 19, 2019

			Jul 19		Aug 19		Sep 19		Oct 19		Nov 19		Dec 19		Jan 20		Feb 20		Mar 20		Apr 20		May 20		Jun 20		TOTAL	
EXPENSE																												
	Administrative Fees	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	8,333	\$	100,000	
	Subcontractors	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	100	\$	1,200	
	Subtotal	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	8,433	\$	101,200	
	Bank Fees	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	360	\$	4,320	
	Board Meeting Expense					\$	100	\$	100	\$	100			\$	100			\$	100					\$	100	\$	600	
	Dues and Subscriptions																									\$	-	
	Insurance (D&O)													\$	2,000											\$	2,000	
	Licenses and Fees							\$	75																	\$	75	
	Postage and Shipping	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	40	\$	480	
	Professional Fees - Audit	\$	8,500																							\$	8,500	
	Professional Fees - Legal	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	25,000	
	Public Information Expense	•																								\$	-	
	Website					\$	525																			\$	525	
	Subtotal	\$	10,983	\$	2,483	\$	3,108	\$	2,658	\$	2,583	\$	2,483	\$	4,583	\$	2,483	\$	2,583	\$	2,483	\$	2,483	\$	2,583	\$	41,500	
TOTAL EXPENSE		\$	19,417	\$	10,917	\$	11,542	\$	11,092	\$	11,017	\$	10,917	\$	13,017	\$	10,917	\$	11,017	\$	10,917	\$	10,917	\$	11,017	\$ ·	142,700	
												-																

NHVA New Hampshire Vaccine Association

Contact

- Patrick Miller, MPH
- Executive Director, NHVA
- pmiller@helmsco.com
- 603-225-6633